Pharmaceuticals - Fort Collins, Colorado, United States
CETYA Therapeutics develops drugs targeting epigenetic mechanisms for unmet medical needs. Our lead technology is a best-in-class series of class I isoform specific histone deacetylase inhibitors that hold significant promise to overcome the clinical limitations of first generation HDACi's. We are developing our first lead compounds for applications in autoimmune disease and oncology. CETYA Therapuetics is also developing new cutting edge compounds that will leverage the parallel and synergistic nature of epigenetic regulatory networks.
Gmail
WordPress.org
Google Tag Manager
Mobile Friendly
Flywheel